Price movement over the last 24 hours
Alcon AG vs American Tower Corp — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while American Tower Corp trades at $164.61 (market cap $76.99B). The key difference: American Tower Corp is far larger — about 2.4× Alcon AG's market cap, and American Tower Corp pays the higher dividend (4.22%). Which is the better fit depends on your goals.
| ALC | AMT | |
|---|---|---|
Market Cap | $32.69B | $76.99B |
Sector | Health | Real Estate |
52-Week High | $92.22 | $232.35 |
52-Week Low | $62.02 | $162.11 |
Enterprise Value | $36.28B | $120.51B |
Dividend Yield | 0.54% | 4.22% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
AMT trades at $165.25, down 0.47% on the day, with a bearish technical signal from moving averages and oscillators. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Strong profitability is evident with a net margin of 26.81% and ROE of 82.19%, though valuation ratios like P/E of 26.15 and P/B of 21.44 appear elevated. Recent news highlights steady revenue growth and sustainability initiatives.
The outlook remains positive with a consensus price target of $217, implying significant upside, supported by 38 buy ratings and no sell recommendations. Risks include high debt levels and competitive pressures from satellite technology. The stock offers a solid dividend yield, with the next payment scheduled for July 13, 2026.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →